Mesh and What Changed After the Inquiries

The 2018 measure on vaginal mesh in England was a period of restricted practice and high vigilance rather than a ban, six conditions were set for lifting it and only one was met, and the Cumberlege review that followed stated that conservative measures must be offered to women before surgery. That last sentence is why the pathway on this site runs physiotherapy first, and it is a policy position rather than an opinion¹.

I have never had mesh surgery and my own condition was treated conservatively, so this is not a personal account. It is here because when I was finally offered a supervised programme, nobody explained why the ordering of the pathway was emphatic rather than casual, and the answer turned out to be recent, documented and specific. Read red flags and when to stop and get checked first.

What happened, in the right order

Three dates circulate for the same event and getting them straight matters.

The primary document is a letter to acute trust chief executives and medical directors dated 9 July 2018, headed “Vaginal mesh: high vigilance restriction period: immediate action required, all cases should be postponed if it is clinically safe to do so”, signed by the National Medical Director of NHS England and the Executive Medical Director and Chief Operating Officer of NHS Improvement.

The sequence: the Independent Medicines and Medical Devices Safety Review recommended it, NHS England and NHS Improvement issued the operational letter on 9 July 2018, the Government announced it on 10 July 2018 with a news story dated 11 July, and the medicines and devices regulator published its note on 17 July 2018.

The scope: a national pause on surgical mesh or tape for stress urinary incontinence and for urogynaecological prolapse where the mesh is inserted through the vaginal wall, implemented as a period of restricted practice and high vigilance. The letter records a detail worth quoting because it is so often assumed otherwise: “There is no concurrent change in the evidence base.”

Restriction, not ban

The distinction is not pedantry, because it changes what a woman is being told when she is offered or refused an operation.

The regulator’s note of 17 July 2018 stated that these procedures had not been banned and that during the pause they would continue to be used when there was no viable alternative and after close and comprehensive consultation between patient and clinician. NHS information still describes the position in similar terms, noting that it may not currently be possible to have vaginal mesh surgery for urinary incontinence on the NHS².

So “mesh was banned” is inaccurate, and so is “nothing changed”. What changed was that the default became postponement, with continued use confined to cases meeting those conditions.

The six conditions, and the one that was met

This is the detail most often reported wrongly, usually as five.

The conditions set for lifting the restriction were: appropriately trained and regularly practising surgeons; reporting of every procedure to a national database; a register identifying every woman operated on; complication reporting to the regulator linked to that register; identification and accreditation of specialist centres; and publication of NICE guidance on mesh for stress urinary incontinence.

Only the last was met, by NICE NG123 in April 2019³. Five conditions concerning who operates, what is recorded, and how harm is tracked remained unmet at the point the restriction was extended.

That is a more interesting fact than the headline, because it says something about what the pause was for. It was not primarily a judgement that the device did not work. It was a judgement that the system around it could not yet demonstrate who was implanting it, into whom, with what results.

What the Cumberlege review said

The Independent Medicines and Medical Devices Safety Review, chaired by Baroness Cumberlege, published First Do No Harm on 8 July 2020. It examined Primodos, sodium valproate and pelvic mesh, it “met and listened to over 700 people”, and it made 9 numbered recommendations¹.

A count of 50 “Actions for Improvement” is frequently attached to that report. This site does not publish it, because the 9 recommendations are confirmed and the count of 50 is not.

Four paragraphs matter for a reader deciding about treatment¹:

• Paragraph 5.59: “Conservative measures must be offered to women before surgery. We are concerned that specialist pelvic floor physiotherapy cannot match the demand; further resource is needed.”
• Paragraph 5.57: the review heard from a number of women who underwent mesh surgery for relatively minor stress urinary incontinence, without having first had or having been offered conservative treatment, and who were living with devastating mesh-related complications.
• Paragraph 5.11: mesh use should be considered a last-line option after conservative non-surgical options and after consideration of non-mesh surgery, and the conditions attached to the pause had not yet been met.
• Paragraph 5.123: pelvic floor education should be encouraged in schools and certainly in antenatal classes, and the NHS should adopt the French model for universal postnatal pelvic floor rehabilitation.

The review also took evidence from the Chartered Society of Physiotherapy that the size of the specialist workforce is insufficient to provide pelvic floor muscle training to all those who require it⁴. Both halves of that belong on this page. A recommendation that conservative treatment must come first, and an acknowledgement in the same paragraph that the service cannot meet demand, is an honest description of the situation rather than a contradiction.

What NICE withdrew, and when

One specific withdrawal, and it is what the June 2019 update consisted of.

NG123 was published on 2 April 2019 and last updated on 24 June 2019, and has not been updated since³. Recommendations 1.8.21 and 1.8.22, on transvaginal mesh for recurrent anterior wall prolapse, were withdrawn in June 2019, and that withdrawal is the update.

So a guideline that carries an April 2019 publication date differs from its original text in exactly this area, which is worth knowing if you are reading an older summary of it.

What the surgical conversation looks like now

Narrower, and explicitly sequenced after conservative treatment.

NICE recommendation 1.5.2 sets out the options when non-surgical management for stress urinary incontinence has failed and a woman wishes to consider surgery: colposuspension, open or laparoscopic, or an autologous rectus fascial sling, including the option of a retropubic mid-urethral mesh sling subject to recommendations 1.5.7 to 1.5.11³.

For prolapse, recommendation 1.8.1 says to offer surgery to women whose symptoms have not improved with or who have declined non-surgical treatment³. That second clause is doing important work: an informed refusal is a legitimate route to a surgical conversation, and nobody has to prove they suffered adequately through a programme they had decided against.

Stress urinary incontinence and pelvic organ prolapse cover those pathways from the condition end, and when physiotherapy is not enough covers what a fair trial is and what the next conversation contains.

Where the restriction stands now, stated carefully

At the most recent authoritative statements this site could trace, it is still in place, and the site describes it exactly that way rather than as a 2026 status.

The Royal College of Obstetricians and Gynaecologists states that a period of restriction was put in place in England in July 2018, was extended in 2019, and remains in place, on a page carrying no date⁵. NHS information states that it may not be possible to have vaginal mesh surgery for urinary incontinence on the NHS, on a page last reviewed on 15 June 2023². No post-2023 government primary source was traceable.

Two dated statements, neither of them from 2026, is what the evidence supports. A site that wrote “mesh remains restricted in 2026” would be asserting something it has not checked, and this is a subject where that kind of drift has done real harm.

Why this history sits on a physiotherapy site

Because it converts “first-line” from a scheduling preference into a documented requirement.

The evidence for conservative treatment stands on its own. In a Cochrane review of 31 trials and 1,817 women, 56% of women with stress urinary incontinence were cured with pelvic floor muscle training against 6% of controls receiving no treatment or an inactive control, a risk ratio of 8.38 with a 95% confidence interval of 3.68 to 19.07, graded high certainty from 4 trials and 165 women⁶. For prolapse the effect is real and modest: in the POPPY trial of 447 women, individualised training improved symptom scores by an adjusted 1.52 points on a 0 to 28 scale at 12 months, with a 95% confidence interval of 0.46 to 2.59 and only 66% of women still in the trial at that point⁷.

NICE puts a supervised programme of at least 3 months first for stress or mixed urinary incontinence and asks clinicians to consider at least 16 weeks for symptomatic stage 1 or 2 prolapse³, with at least one review during the programme and one at the end⁸.

What the inquiries added was the reason that ordering is stated so firmly. Women were harmed by a sequence that ran the other way. Why symptoms get dismissed and how to be heard covers the everyday version of the same failure, and pelvic floor physiotherapy sets out the treatment that the review said must be offered first.